Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 524-533, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-939742
ABSTRACT
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer. Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients, with tolerable toxicity. Nivolumab with chemotherapy has been approved by Food and Drug Administration (FDA) as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting. There is the need for further evaluation of long-term efficacy, side effects or surgical issues for neoadjuvant immunotherapy in non-small cell lung cancer.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Terapia Neoadyuvante
/
Antineoplásicos Inmunológicos
/
Nivolumab
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS